Intermediate prognosis in metastatic germ cell tumours—outcome and prognostic factors

Christoph Seidel, Gedske Daugaard, Alexey Tryakin, Andrea Necchi, Gabriella Cohn Cedermark, Olof Ståhl, Marcus Hentrich, Margarida Brito, Costantine Albany, Fadi Taza, Arthur Gerl, Karin Oechsle, Carsten Bokemeyer

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: For metastatic germ cell tumour patients with intermediate prognosis (IPGCT) according to the IGCCCG classification 5-year overall survival (OS) rates of 79% were described, but recent data suggest significant changes. Patients and methods: To compare the outcome of current IPGCT with former patients and to find new prognosticators a retrospective observational study was performed. Eligibility criteria were: age ≥16 years, diagnosed between 1979 and 2014. Primary end-point was the 5-year OS rate. Results: This database includes 707 IPGCT: group 1 was diagnosed 1979–1996 (n = 237), and group 2 1997–2014 (n = 470). Median follow-up was 8.6 years (IQR: 14.4). Group 1 and 2 received first-line treatment with BEP (median 4 cycles; range 1–6) in 99% (group 1) and 95% (group 2), respectively. The proportion of first-line chemotherapy responders (CR and marker negative PR) was similar: 94% (group 1) and 96% (group 2), respectively (P = 0.290), but OS was superior in group 2 with a 5-year OS rate of 89% compared with 83% in group 1 (P = 0.035). In refractory disease, high-dose chemotherapy and treatment beyond second line was performed more often in group 2. A lactate dehydrogenase (LDH) cut-off value of 2 ULN (P = 0.002; HR 2.121) and alpha-fetoprotein (AFP) levels of 6200 IU/ml (P = 0.032; HR 2.155) pre-chemotherapy were independent prognosticators for OS in a multivariate analysis. Conclusion: Outcome of IPGCT has improved and is now closer to the good prognosis category. LDH and AFP levels represent potential markers to stratify IPGCT before treatment initiation.

Original languageEnglish (US)
Pages (from-to)16-25
Number of pages10
JournalEuropean Journal of Cancer
Volume94
DOIs
StatePublished - May 1 2018

Fingerprint

Germ Cells
Survival Rate
alpha-Fetoproteins
L-Lactate Dehydrogenase
Drug Therapy
Survival
Germ Cell and Embryonal Neoplasms
Observational Studies
Therapeutics
Multivariate Analysis
Retrospective Studies
Databases

Keywords

  • IGCCCG classification
  • Intermediate prognosis
  • Outcome
  • Prognostic factors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Seidel, C., Daugaard, G., Tryakin, A., Necchi, A., Cohn Cedermark, G., Ståhl, O., ... Bokemeyer, C. (2018). Intermediate prognosis in metastatic germ cell tumours—outcome and prognostic factors. European Journal of Cancer, 94, 16-25. https://doi.org/10.1016/j.ejca.2018.01.113

Intermediate prognosis in metastatic germ cell tumours—outcome and prognostic factors. / Seidel, Christoph; Daugaard, Gedske; Tryakin, Alexey; Necchi, Andrea; Cohn Cedermark, Gabriella; Ståhl, Olof; Hentrich, Marcus; Brito, Margarida; Albany, Costantine; Taza, Fadi; Gerl, Arthur; Oechsle, Karin; Bokemeyer, Carsten.

In: European Journal of Cancer, Vol. 94, 01.05.2018, p. 16-25.

Research output: Contribution to journalArticle

Seidel, C, Daugaard, G, Tryakin, A, Necchi, A, Cohn Cedermark, G, Ståhl, O, Hentrich, M, Brito, M, Albany, C, Taza, F, Gerl, A, Oechsle, K & Bokemeyer, C 2018, 'Intermediate prognosis in metastatic germ cell tumours—outcome and prognostic factors', European Journal of Cancer, vol. 94, pp. 16-25. https://doi.org/10.1016/j.ejca.2018.01.113
Seidel, Christoph ; Daugaard, Gedske ; Tryakin, Alexey ; Necchi, Andrea ; Cohn Cedermark, Gabriella ; Ståhl, Olof ; Hentrich, Marcus ; Brito, Margarida ; Albany, Costantine ; Taza, Fadi ; Gerl, Arthur ; Oechsle, Karin ; Bokemeyer, Carsten. / Intermediate prognosis in metastatic germ cell tumours—outcome and prognostic factors. In: European Journal of Cancer. 2018 ; Vol. 94. pp. 16-25.
@article{7f020b27142b44428665daa211107506,
title = "Intermediate prognosis in metastatic germ cell tumours—outcome and prognostic factors",
abstract = "Background: For metastatic germ cell tumour patients with intermediate prognosis (IPGCT) according to the IGCCCG classification 5-year overall survival (OS) rates of 79{\%} were described, but recent data suggest significant changes. Patients and methods: To compare the outcome of current IPGCT with former patients and to find new prognosticators a retrospective observational study was performed. Eligibility criteria were: age ≥16 years, diagnosed between 1979 and 2014. Primary end-point was the 5-year OS rate. Results: This database includes 707 IPGCT: group 1 was diagnosed 1979–1996 (n = 237), and group 2 1997–2014 (n = 470). Median follow-up was 8.6 years (IQR: 14.4). Group 1 and 2 received first-line treatment with BEP (median 4 cycles; range 1–6) in 99{\%} (group 1) and 95{\%} (group 2), respectively. The proportion of first-line chemotherapy responders (CR and marker negative PR) was similar: 94{\%} (group 1) and 96{\%} (group 2), respectively (P = 0.290), but OS was superior in group 2 with a 5-year OS rate of 89{\%} compared with 83{\%} in group 1 (P = 0.035). In refractory disease, high-dose chemotherapy and treatment beyond second line was performed more often in group 2. A lactate dehydrogenase (LDH) cut-off value of 2 ULN (P = 0.002; HR 2.121) and alpha-fetoprotein (AFP) levels of 6200 IU/ml (P = 0.032; HR 2.155) pre-chemotherapy were independent prognosticators for OS in a multivariate analysis. Conclusion: Outcome of IPGCT has improved and is now closer to the good prognosis category. LDH and AFP levels represent potential markers to stratify IPGCT before treatment initiation.",
keywords = "IGCCCG classification, Intermediate prognosis, Outcome, Prognostic factors",
author = "Christoph Seidel and Gedske Daugaard and Alexey Tryakin and Andrea Necchi and {Cohn Cedermark}, Gabriella and Olof St{\aa}hl and Marcus Hentrich and Margarida Brito and Costantine Albany and Fadi Taza and Arthur Gerl and Karin Oechsle and Carsten Bokemeyer",
year = "2018",
month = "5",
day = "1",
doi = "10.1016/j.ejca.2018.01.113",
language = "English (US)",
volume = "94",
pages = "16--25",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Intermediate prognosis in metastatic germ cell tumours—outcome and prognostic factors

AU - Seidel, Christoph

AU - Daugaard, Gedske

AU - Tryakin, Alexey

AU - Necchi, Andrea

AU - Cohn Cedermark, Gabriella

AU - Ståhl, Olof

AU - Hentrich, Marcus

AU - Brito, Margarida

AU - Albany, Costantine

AU - Taza, Fadi

AU - Gerl, Arthur

AU - Oechsle, Karin

AU - Bokemeyer, Carsten

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Background: For metastatic germ cell tumour patients with intermediate prognosis (IPGCT) according to the IGCCCG classification 5-year overall survival (OS) rates of 79% were described, but recent data suggest significant changes. Patients and methods: To compare the outcome of current IPGCT with former patients and to find new prognosticators a retrospective observational study was performed. Eligibility criteria were: age ≥16 years, diagnosed between 1979 and 2014. Primary end-point was the 5-year OS rate. Results: This database includes 707 IPGCT: group 1 was diagnosed 1979–1996 (n = 237), and group 2 1997–2014 (n = 470). Median follow-up was 8.6 years (IQR: 14.4). Group 1 and 2 received first-line treatment with BEP (median 4 cycles; range 1–6) in 99% (group 1) and 95% (group 2), respectively. The proportion of first-line chemotherapy responders (CR and marker negative PR) was similar: 94% (group 1) and 96% (group 2), respectively (P = 0.290), but OS was superior in group 2 with a 5-year OS rate of 89% compared with 83% in group 1 (P = 0.035). In refractory disease, high-dose chemotherapy and treatment beyond second line was performed more often in group 2. A lactate dehydrogenase (LDH) cut-off value of 2 ULN (P = 0.002; HR 2.121) and alpha-fetoprotein (AFP) levels of 6200 IU/ml (P = 0.032; HR 2.155) pre-chemotherapy were independent prognosticators for OS in a multivariate analysis. Conclusion: Outcome of IPGCT has improved and is now closer to the good prognosis category. LDH and AFP levels represent potential markers to stratify IPGCT before treatment initiation.

AB - Background: For metastatic germ cell tumour patients with intermediate prognosis (IPGCT) according to the IGCCCG classification 5-year overall survival (OS) rates of 79% were described, but recent data suggest significant changes. Patients and methods: To compare the outcome of current IPGCT with former patients and to find new prognosticators a retrospective observational study was performed. Eligibility criteria were: age ≥16 years, diagnosed between 1979 and 2014. Primary end-point was the 5-year OS rate. Results: This database includes 707 IPGCT: group 1 was diagnosed 1979–1996 (n = 237), and group 2 1997–2014 (n = 470). Median follow-up was 8.6 years (IQR: 14.4). Group 1 and 2 received first-line treatment with BEP (median 4 cycles; range 1–6) in 99% (group 1) and 95% (group 2), respectively. The proportion of first-line chemotherapy responders (CR and marker negative PR) was similar: 94% (group 1) and 96% (group 2), respectively (P = 0.290), but OS was superior in group 2 with a 5-year OS rate of 89% compared with 83% in group 1 (P = 0.035). In refractory disease, high-dose chemotherapy and treatment beyond second line was performed more often in group 2. A lactate dehydrogenase (LDH) cut-off value of 2 ULN (P = 0.002; HR 2.121) and alpha-fetoprotein (AFP) levels of 6200 IU/ml (P = 0.032; HR 2.155) pre-chemotherapy were independent prognosticators for OS in a multivariate analysis. Conclusion: Outcome of IPGCT has improved and is now closer to the good prognosis category. LDH and AFP levels represent potential markers to stratify IPGCT before treatment initiation.

KW - IGCCCG classification

KW - Intermediate prognosis

KW - Outcome

KW - Prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=85042729562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042729562&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2018.01.113

DO - 10.1016/j.ejca.2018.01.113

M3 - Article

C2 - 29505967

AN - SCOPUS:85042729562

VL - 94

SP - 16

EP - 25

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -